Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $32 from $33 and keeps a Buy rating on the shares. The firm noted management narrowed its 2024E sales outlook for Nuplazid to the top end of its prior range, and to the lower end of its prior range for Daybue. With intense investor focus around Daybue sales, Canaccord views this as a solid outcome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals participates in a conference call with JPMorgan
- Acadia Pharmaceuticals Sees Revenue Growth and Strategic Advances
- Acadia Pharmaceuticals reports Q3 EPS , consensus 14c
- Acadia Pharmaceuticals sees FY24 revenue $940M-$960M, consensus $952.5M
- Acadia Pharma sells Rare Pediatric Disease Priority Review Voucher for $150M
Questions or Comments about the article? Write to editor@tipranks.com